TruBridge, Inc.

As of November 8, 2023, TruBridge, Inc. is considered overvalued with a negative return on equity of -5.10% and a price-to-book value of 2.14, indicating a risky valuation compared to peers like MediaAlpha and OneSpan, despite a recent strong return of 75.06% over the past year.

As of November 8, 2023, TruBridge, Inc. is considered overvalued with a risky valuation grade, reflected by key ratios indicating it trades at a premium compared to earnings potential and struggles with negative ROE and low ROCE compared to peers, despite a strong one-year stock return of 118.60%.

As of April 1, 2025, TruBridge, Inc. shows a mildly bullish trend supported by daily moving averages, but caution is advised due to mildly bearish weekly MACD and KST indicators.

As of March 2022, the management team of TruBridge, Inc. includes Glenn Tobin (Independent Chair), John Boyd Douglas (President & CEO), David Dye (Director & Chief Growth Officer), and several Independent Directors: Regina Benjamin, Christopher Hjelm, Charles Huffman, and W. Austin Mulherin. This team combines executive leadership with independent oversight to guide the company.

TruBridge, Inc. provides healthcare IT solutions for rural and community hospitals and post-acute care facilities, with recent net sales of $87 million and a market cap of $349.63 million. The company is currently loss-making, with a debt-to-equity ratio of 0.94 and a return on equity of -5.10%.

As of Jun 18, TruBridge, Inc. has a market capitalization of 349.63 million and net sales of 343.13 million, with a net profit of -19.38 million for the latest four quarters. Shareholder's funds are 168.69 million and total assets are 420.59 million as of Dec 24.